Analyze CGEN

ShareShare on WhatsApp Share on Facebook Share on X

Compugen Ltd. (CGEN)

Market cap$225.11M

$2.38

+4.39%

Price source: Yahoo · live price · as of 23:00

About the company

Market cap

$225.11M

P/E

5.95

Beta

2.77

Employees

Sector: HealthcareIndustry: BiotechnologyExchange: NasdaqCMCountry: Israel Website

What the company does

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Next earnings

2026-08-03

Est. EPS

-0.09

Est. revenue

$1.28M

Dividend

—

Management & founders

Dr. Anat Cohen-Dayag Ph.D.Executive Chair

Dr. Eran Ophir Ph.D.CEO, President & Director

Dr. Pierre Ferre Ph.D.Chief Operating Officer

Dr. Zurit Levine Ph.D.Senior Vice President of Business Development

Ms. Michelle Mahler M.D.Chief Medical Officer

Mr. David Silberman CPAChief Financial Officer

Day range

$2.28$2.39

52-week range

$1.30$3.24

Price alert on CGEN

Get an in-app and mobile alert every time CGEN crosses a price you set.

Compugen Ltd. (CGEN) is trading around $2.38 (+4.39% on the last session). Its 52-week range runs from $1.30 to $3.24. Technically: 6 buy signals, 1 sell and 5 neutral. It belongs to the Healthcare sector (Biotechnology), with a P/E of 6.0 and a 225M$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

CGEN stock FAQ

What is CGEN's current price?

CGEN is trading around $2.38 (+4.39%), as of 23:00 per Yahoo · live price.

What is CGEN's 52-week price range?

Over the last 52 weeks CGEN ranged between a $1.30 low and a $3.24 high.

Which sector does CGEN belong to?

CGEN belongs to the Healthcare sector, Biotechnology industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy